AGI 1000
Latest Information Update: 26 Jun 2002
Price :
$50 *
At a glance
- Originator AtheroGenics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Jun 2002 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 29 Mar 2001 No-Development-Reported for Solid tumours in USA (Unknown route)
- 10 Nov 1998 New profile